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Abstract
Introduction: The prevalence of diabetes is on the increase and an estimated 239 million people worldwide 
are expected to have the condition by the year 2020 (1). Diabetes mellitus (DM) represents a serious health 
care challenge. The aim of the study was to evaluate the patient clinical characteristics and risk factors for 
long term complications in the endocrine clinic of Hospital Penang, Malaysia. 
Methods: Descriptive Prospective cross-sectional study design was chosen. To achieve a power of 0.7 with 
alpha set at 0.05, 186 subjects were required for the study but researcher increase the sample to 297 in case 
of drop out. Self-developed data collection form was used to collect the patient information. 
Results: 297 (100%) patients were enrolled from OPD diabetic clinic of Hospital Palau Pinang. Among the 
sample 150 (50.5%) were males and rest 147 (49.5%) females. Malay males mean weight at the time of diag-
nosis signifi cantly higher (p<0.001,) as compared to other ethnics, same results found among Malay females 
(p<0.001). Findings suggested increased number of risk factors among the study population. Finding also 
showed that hypertension found among all the classes of diagnosis. Signifi cant variable are diagnosis class 
and medication consideration.
Conclusion of the study suggested that majority of patients are at high risk of long-term complications and 
comorbidies. It has been found that increased rate of risk factors have been found among the study popula-
tion and non-signifi cant to sociodemographic differences. © 2012 All rights reserved
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Introduction
Th e prevalence of diabetes is on the increase and 
an estimated 239 million people worldwide are 
expected to have the condition by the year 2020 
(1). Diabetes mellitus (DM) represents a serious 
health care challenge. It is a heterogeneous disor-
der characterized by varying degrees of insulin re-
sistance and insulin defi ciency, which leads to dis-
turbances in glucose homeostasis. It is commonly 
associates with prolonged ill health and premature 
death (2). Th e mortality rate in patients with DM 
may be up to eleven times higher than in per-
sons without the disease (3, 4). DM is the leading 
cause of blindness, renal failure and foot and leg 
amputations in adults in developed countries (1). 
Th e World Health Organization (WHO) clas-
sifi cation system of DM recognized two major 
forms of diabetes (5); Type 1 diabetes mellitus 
(DM), formerly known as insulin dependent dia-
betes mellitus (IDDM; patient is dependent on 
exogenous insulin for survival) and Type 2 DM, 
formerly known as non-insulin dependent dia-
betes mellitus (NIDDM; patient is not necessary 
dependent on exogenous insulin for survival).
Teamwork and collaboration are essential com-
ponents of successful DM management, both to 
prevent complications and maintain the patients’ 
health-related quality of life (HRQOL) over a 
* Corresponding author: Syed Wasif Gillani
School of Pharmaceutical Sciences, Universiti Sains 
Malaysia, 11800, Gelugor, Pulau Pinang, Malaysia
Phone: +60174203027; Fax: +604-6570017
e-mail: wasifgillani@gmail.com
Submitted: 13 May 2012 / Accepted: 23 July 2012
105JOURNAL OF HEALTH SCIENCES 2012; 2 (2)
SYED WASIF GILLANI ET AL.: RISK FACTORS FOR LONG TERM COMPLICATIONS AMONG 
PATIENTS OF ENDOCRINE CLINIC IN HOSPITAL PENANG, MALAYSIA
lifetime of coping with the disease (1). Type 1 
DM is characterized by insulin defi ciency result-
ing from immune-mediated pancreatic beta-cell 
destruction. Th e most serious acute consequence 
of this is ketoacidosis. Pancreatic beta-cell de-
struction eventually results in absolute insulin 
defi ciency (1). Type 1 DM accounts for approxi-
mately ten percent of all DM cases. Type 2 DM 
is generally characterized by peripheral insulin 
resistance with relative insulin defi ciency to pre-
dominant insulin secretory defeat with insulin 
resistance (1). Type 2 DM accounts for approxi-
mately ninety percent of all DM cases. Th e ma-
jor risk factors in the development of type 2 DM 
are (3); Family history, Obesity, Race/ethnicity, 
Increasing age (especially greater than forty fi ve 
years), Previous identifi ed impaired fasting glu-
cose or impaired glucose tolerance, Hypertension, 
Hyperlipidemia and History of gestational DM.
 Th ere is evidence that good glycaemic control 
can slow or prevent the development of diabetes 
complications (6-10). Th e Diabetes Control and 
Complication Trial (DCCT) demonstrated the as-
sociation between the degree of glycaemic control 
and the development of microvascular complica-
tions in type 1 DM patients (11-12). Th e DCCT 
determined that there was an approximately 
50% reductions in microvascular complications 
in the intensive treatment group and a non-sig-
nifi cant tendency to fewer major cardiovascular 
events. Intensive control was accompanied by 
a signifi cantly between the groups. Th e DCCT 
investigators did advice caution in extending 
the fi ndings to patients with type 2 DM without 
careful regard for age and coexisting diseases. 
Th e United Kingdom Prospective Diabetes Study 
(UKPDS) was the largest scale long-term interven-
tion study in newly diagnosed type 2 DM patients 
and involved over 5000 patients. Th e UKPDS used 
an intensive blood glucose control policy, which 
achieved a medium HbA1c of 7% compared with 
7.9% in those randomized to conventional treat-
ment over a median 10 years follow-up (9). Th e 
UKPDS confi rmed the benefi t of intense glycae-
mic control on microvascular disease in type 2 
DM patients (4, 8-10, 13-20). Th e aim of the study 
to evaluate the patient clinical characteristics and 
risk factors for long term complications in the 
endocrine clinic of Hospital Penang, Malaysia. 
Methods 
Study design
Th is study aimed to describe the risk factors and 
association among sociodemographics, hence 
Descriptive Prospective cross-sectional study de-
sign was chosen. Managing diabetes is a lifelong 
process and requires total commitment from in-
dividuals with diabetes. Hence the framework of 
this study was based on the principle of eight risk 
factors (RF). RF1-Diabetes, RF2- Hypertension, 
RF3- Hyperlipidemia, RF4- Smoking, RF5-Male > 
45years, RF6=Female > 55years, RF7- Hypoglyce-
mia, RF8- No exercise (3x/week > 20min). RF1-
Diabetes, since all the patients are from endocrine 
clinic so the rational eff ect of this variable is 100%. 
Setting
As 70% of people with diabetes in Malaysia re-
ceive treatment in the government healthcare 
system, (21) data was collected from govern-
ment healthcare settings. Th e general hospital 
is the main government hospital in the Penang 
state and is situated within the city area off er-
ing tertiary care. Subjects were not recruited 
from private clinics and hospitals due to prob-
lems with accessibility and diff erences in socio-
economic status which could bias the outcomes.
Sample Size
Th e required sample size was calculated with 
power analysis using the procedure provided by 
the Polit and Hungler (22). Th e power was set at 
0.80 with alpha being set at 0.05. Since the value 
of the eff ect size (Gamma), was unavailable from 
previous similar studies and the pilot study sam-
ple size was small (19 subjects), the investigator 
chose to use the conversion based on the eff ect 
size convention table in Polit and Hungler (22). 
Polit and Hungler (22) advise to use medium ef-
fect size ranging from 0.2-0.3 for nursing studies. 
Th is provided a range of sample size from 88-197 
subjects. For logistical reasons the study had to 
be a manageable size within the period of study, 
so the investigator chose the sample size using 
the medium eff ect size of Gamma y = 0.25. To 
achieve a power of 0.7 with alpha set at 0.05, 186 
subjects were required for the study but research-
er increase the sample to 297 in case of drop out.
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Inclusion criteria. Subjects who met the follow-
ing criteria were recruited: non-pregnant adults 
with either Type1 or Type 2 diabetes regardless 
of gender and ethnicity, 18 years and above (legal 
age for consent), diagnosed with diabetes with 
year of more, speaking and understanding either 
English, Bahasa Malaysia, Mandarin, Chinese 
dialects (Cantonese, Hokkien, Teow-chew) be-
cause these were the languages used during the 
interview, having poor diabetes control during the 
last one year. Even though glycated haemoglobin 
(HbA1c) is the gold standard for glycaemic as-
sessment, it was not consistently measured for all 
diabetic patients in the healthcare system where 
the study was done. Th erefore for the purpose of 
this study, poor diabetes control was defi ned as 
the mean of minimum of three fasting blood glu-
cose (FBG) readings of more than 7 mmol/L in 
the last year. Prior studies have shown that FBG of 
more than 7 mmol/L is associated with increased 
micro-and macro-vascular complications (23-26).
Exclusion criteria. Th e following subjects were ex-
cluded: Were adults 18 years of age and more with 
either Type 1 of Type 2 diabetes unable to answer 
the questionnaires independently, such as having 
unstable medical condition, mental illness, and se-
nility or hearing impairment. Th is was to avoid as-
sistance from family members to cares that could 
introduce bias in the data collection; had poor vi-
sion and unable to assess visually the portion sizes 
of their carbohydrate food intake during dietary 
assessment; were women who were pregnant or 
had gestational diabetes due to diff erent criteria on 
standard of control; had record of random blood 
glucose only because the defi nition of poor con-
trol was based on fasting blood glucose readings.
Research Tool
Self-developed data collection form was used to 
collect the patient information.
Ethical issues
Th e Research Ethics Committee of hospi-
tal and the Malaysian Medical Research 
and Ethics Committee approved the study.
Written consents which included information to 
access the subjects’ medical records were taken 
from all participants before the interviews. For 
those who were illiterate and not able to give 
their signature, thumbprints were used instead.
Th e medical records were sourced for two pieces 
of information. First, the subjects’ glycaemic sta-
tus was attained namely fasting blood glucose 
levels to assist the investigator in identifying the 
potential subjects (inclusion criteria). Second, 
the subjects’ current medication(s) were attained 
since research question three sorts to identify any 
relationship between medication concordance 
and poor glycaemic control. No other data was 
extracted from the medical records. Viewing and 
extracting information from the subjects’ medical 
records was done solely by the investigator either 
at the medical in-patient wards or the medical 
outpatient clinics during offi  cial working hours.
Data Collection Procedure
Identifi cation of Subjects. Th is was done ini-
tially by identifying all diabetic subjects. In the 
out-patient department of the hospital, the in-
vestigator worked closely with the nursing staff 
to identify patients with blood glucose tests 
done prior to doctors’ consultation. Th ey were 
familiar with their patients with poor glycae-
mic control or the nurse in-charge identifi ed 
them via the patients’ blood glucose results.
Places of Data Collection. Data collection was 
done in out-patient departments at the doctors’ 
consultation rooms.
Statistical Analysis
Th e analysis was done in both descriptive and infer-
ential statistics to make information in presentable 
form. Data is presented in both graphical and tabu-
lar forms. Th e Statistical package for Social Scienc-
es (SPSS) version 19 ® was used for this analysis. Th e 
level of signifi cance was set at 0.05 for all analysis.
Results
A total of 297 (100%) patients were enrolled 
from OPD diabetic clinic of Hospital Palau 
Pinang. Among the sample 150 (50.5%) were 
Gender F (%) Age mean (±S.D.)
Male 150 (50.5) 58.23 (10.771)
Female 147 (49.5) 59.04 (10.414)
Total 297 (100.0) 58.64 (10.581)
TABLE 1.  Frequency among gender of study population
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males and rest 147 (49.5%) females. Mean age 
distribution among gender is presented in Table 1.
Ethnic distribution among males showed predom-
inance of Chinese with 77 (51.3%) followed by 
Malays 40 (26.7%) and rest 33 (22%) were Indians. 
While among females almost same pattern was 
found. Th e mean ± S.D age diff erences were found 
FIGURE 1.  Clinical risk factors founds among enrolled patients. (RF1 = Diabetes, RF2 = Hypertension, RF3 = Hyperlipidemia, 
RF4 = Smoking, RF5 = Male >45years, RF6=Female>55years, RF7 = Hypoglycemia, RF8 = No exercise (3x/week>20min)).
Gender Ethnic Mean N (%) Std. Deviation
Male
Malay 53.20 40 (26.7) 12.831
Chinese 62.10 77 (51.3) 8.612
Indian 55.03 33 (22) 9.600
Total 58.23 150 (50.5) 10.771
Female
Malay 54.03 36 (24.49) 8.013
Chinese 63.43 81 (55.10) 11.090
Indian 58.30 30 (20.41) 9.063
Total 59.04 147 (49.5) 10.414
Total
Malay 53.61 76 (25.59) 10.627
Chinese 62.75 158 (53.20) 9.959
Indian 56.53 63 (21.21) 9.422
Total 58.64 297 (100.0) 10.581
TABLE 2.  Mean age gender distribution among ethnic
Characteristic
RF2-hypertension
Total N 
(%)
p-
valueYes
N (%)
No
N (%)
Gender
 Male
 Female
Ethnic
 Malay
 Chinese
 Indian
Diagnosis
 IDDM
 Diabetes
 Diabetes and HPT
 Diabetes and 
other complication
Medication 
consideration
 Insulin
 Insulin and oral
 BIDS
 Oral
 Diet and exercise
88 (58.7)
93 (63.2)
44 (57.9)
102 (65.4)
36 (55.4)
3 (100.0)
8 (9.0)
101 (100.0)
69 (66.3)
3 (50.0)
1 6 (66.7)
4 (22.2)
156 (63.4)
2 (66.7)
62 (41.3)
54 (36.8)
32 (42.1)
54 (34.6)
29 (44.6)
-
81 (91.0)
-
35 (33.7)
3 (50.0)
8 (33.3)
14 (77.8)
90 (36.6)
1 (33.3)
150 (100.0)
147 (100.0)
76 (100.0)
156 (100.0)
65 (100.0)
3 (100.0)
89 (100.0)
101 (100.0)
104 (100.0)
6 (100.0)
24 (100.0)
18 (100.0)
246 (100.0)
3 (100.0)
0.417
0.296*
0.000*
0.013*
TABLE 4.  Characteristic determination of RF2 –hypertension 
during study duration
Gender Ethnic Mean N (%) Std. Deviation
Male
Malay 79.17 40 (26.67) 18.936
Chinese 66.64 77 (51.33) 13.003
Indian 69.19 33 (22) 11.314
Total 70.34 150 (50.5) 15.185
Female
Malay 69.38 36 (24.49) 14.896
Chinese 60.53 81 (55.10) 12.766
Indian 59.95 30 (20.41) 11.069
Total 62.37 147 (49.5) 13.382
Total
Malay 74.74 76 (25.59) 17.761
Chinese 63.31 158 (53.20) 13.184
Indian 64.96 63 (21.21) 12.019
Total 66.29 297 (100.0) 14.815
TABLE 3.  Mean weight in kg at diagnosis gender distribution 
among ethnic
Chi-square (*Pearson)
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variable among the three ethnics. Table 2 showed 
the distribution pattern of mean ± S.D of age among 
genders and also among the study population.
Mean age comparison among genders showed 
females have high mean age (59.04 years) as 
compared to males (58.23 years). While com-
paring mean age diff erence among ethnics re-
vealed Chinese mean age is 62.75 years followed 
by Indians with 56.53 years and least age to dis-
ease response among Malays 53.61 years. Mean 
weight of the study population was 66.29kg but 
upon analysis among genders it is found that 
males mean ± S.D (70.34 ± 15.185) is extensively 
higher as compared to females (62.37 ± 13.382).
Further analysis by cross tabulation showed Malay 
males mean weight at the time of diagnosis signifi -
cantly higher (p<0.001, one way ANOVA) as com-
pared to other ethnics, same results found among 
Malay females (p<0.001, one way ANOVA). Table 
3 showed cross-tabulation of mean weight distri-
bution among gender and ethnics at the time of di-
agnosis. At the time of diagnosis body mass index 
(BMI) has been collected and results showed the 
mean BMI of the study population was 25.39 (297, 
100%), among them females have higher BMI 25.79 
as compared to males 24.97 at the time of diagnosis.
Th e Figure 1 presents the percentage distribution of 
clinical risk factors among study population. Clin-
ical risk factors are the individual parameters that 
might lead to increase long-term complications 
or co morbidities. More the clinical risk factors 
among the study population, it will give increase 
possibility to get higher complications. Findings 
suggested increased number of risk factors among 
the study population. Finding also showed that 
hypertension found among all the classes of diag-
nosis. Signifi cant variable are diagnosis class and 
medication consideration. Table 4 provides the de-
scriptive information about the RF-2 hypertension 
during the study duration among selected patients.
Risk factor analysis results showed that hyperlip-
idemia have signifi cant association among gender. 
Further analysis revealed that about 95 (32%) of 
our study population carrying this risk factor and 
majority of them 83 (87.4%) on the oral medica-
tion. Table 5 presented the fi nding of the analysis. 
Similarly smoking fi ndings are presented in Table 6.
Age above then 45 years for male and >55 years 
Characteristic
RF3-hyperlipidemia Total N 
(%)
p-
valueYes N (%) No N (%)
Gender
 Male
 Female
Ethnic
 Malay
 Chinese
 Indian
Diagnosis
 IDDM
 Diabetes
 Diabetes and HPT
 Diabetes and other
 complication
Medication 
consideration
 Insulin
 Insulin and oral
 BIDS
 Oral
 Diet and exercise 
43 (28.7)
52 (35.4)
20 (26.3)
55 (35.2)
20 (30.8)
1 (33.3)
2 (2.2)
4 (4.0)
88 (84.6)
3 (50.0)
6 (25.0)
3 (16.7)
83 (33.7)
-
107 (71.3)
95 (64.6)
56 (73.7)
101 (64.8)
45 (69 .2)
2 (66.7)
87 (97.8)
97 (96.0)
16 (15.4)
3 (50.0)
18 (75.0)
15 (83.3)
163 (66.3)
3 (100.0)
150 (100.0)
147 (100.0)
76 (100.0)
156 (100.0)
65 (100.0)
3 (100.0)
89 (100.0)
101 (100.0)
104 (100.0)
6 (100.0)
24 (100.0)
18 (100.0)
246 (100.0)
3 (100.0)
0.0215
0.258
0.000*
0.274*
TABLE 5.  Characteristic determination of RF3 - hyperlipid-
emia in study population
Chi-square (*Pearson)
Characteristic
RF4-Smoking Total 
N (%)
p-
valueYes N (%) No N (%)
Gender
 Male
 Female
Ethnic
 Malay
 Chinese
 Indian
Diagnosis
 IDDM
 Diabetes
 Diabetes and HPT
 Diabetes and other
 complication
Medication 
consideration
 Insulin
 Insulin and oral
 BIDS
 Oral
 Diet and exercise 
28 (18.7)
4 (2.7)
6 (8.0)
13 (8.3)
12 (18.5)
1 (33.3)
8 (9.0)
8 (7.9)
13 (12.5)
1 (16.7)
3 (12.5)
1 (5.5)
20 (8.1)
-
122 (81.3)
143 (97.3)
70 (92.0)
143 (91.7)
53 (81.5)
2 (66.7)
81 (91.0)
93 (92.1)
91 (87.5)
5 (83.3)
21 (87.5)
17 (94.5)
226 (91.9)
3 (100.0)
150 (100.0)
147 (100.0)
76 (100.0)
156 (100.0)
65 (100.0)
 ˝
3 (100.0)
89 (100.0)
101 (100.0)
104 (100.0)
6 (100.0)
24 (100.0)
18 (100.0)
246 (100.0)
3 (100.0)
0.000
0.441*
0.096*
0.552*
Chi-square (*Fisher exact)
TABLE 6.  Characteristic determination of RF4-Smoking in 
study population
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for females is important factor for complications 
and long-term medical problems. Upon analy-
sis of this variable we fi nd similar results of sig-
nifi cant association with ethnic, diagnosis class 
and medication consideration. Results showed 
that 114 (76%) of our study males are > 45 years 
while 90 (61.2%) of females were > 55 years. De-
tailed descriptive data is presented in Table 7 & 8.
Characteristic N (%) p-value
Ethnic
 Malay
 Chinese
 Indian
Diagnosis
 IDDM
 Diabetes
 Diabetes and HPT
 Diabetes and other complication
Medication consideration
 Insulin
 Insulin and oral
 BIDS
 Oral
 Diet and exercise
27 (23.7)
65 (57.0)
22 (19.3)
1 (0.9)
27 (23.7)
43 (37.7)
43 (37.7)
1 (0.9)
12 (10.5)
5 (4.4)
94 (82.5)
2 (1.7)
0.000
0.000
0.000
TABLE 7.  Characteristic determination of RF5-Male>45 
years (N=114/150) among male in study population
Characteristic N (%) p-value
Ethnic
 Malay
 Chinese
 Indian
Diagnosis
 IDDM
 Diabetes
 Diabetes and HPT
 Diabetes and other complication
Medication consideration
 Insulin
 Insulin and oral
 BIDS
 Oral
 Diet and exercise
16 (17.8)
58 (64.4)
16 (17.8)
1 (11.1)
15 (16.7)
32 (35.5)
42 (46.7)
3 (33.3)
6 (6.7)
1 (1.1)
79 (87.8)
1 (1.1)
0.000
0.000
0.000
TABLE 8.  Characteristic determination of RF6-Female > 55 
years (N=90/147) among female in study population
TABLE 9.  Characteristic determination of RF7-Hypoglycae-
mia in study population
Chi-square (*fi sher exact)
Characteristic
RF8-No Exercise 
(3x/week>20 min) Total N (%) p-value
Yes N (%) No N (%) 
Gender
 Male
 Female
Ethnic
 Malay
 Chinese
 Indian
Diagnosis
 IDDM
 Diabetes
 Diabetes and HPT
 Diabetes and other 
 complication
Medication 
consideration
 Insulin
 Insulin and oral
 BIDS
 Oral
 Diet and exercise 
41 (27.3)
38 (25.9)
21 (27.6)
38 (24.4)
18 (27.7)
-
33 (37.1)
18 (17.8)
27 (26.0)
3 (50.0)
4 (16.7)
4 (22.2)
63 (25.6)
-
109 (72.7)
109 (74.1)
55 (72.4)
118 (75.6)
47 (72.3)
3 (100.0)
56 (62.9)
83 (82.2)
77 (74.0)
3 (50.0)
20 (83.3)
14 (77.8)
183 (74.4)
3 (100.0)
150 (100.0)
147 (100.0)
76 (100.0)
156 (100.0)
65 (100.0)
3 (100.0)
89 (100.0)
101 (100.0)
104 (100.0)
6 (100.0)
24 (100.0)
18 (100.0)
246 (100.0)
3 (100.0)
0.730
0.032
0.001*
0.037*
Chi-square (*fi sher exact)
TABLE 10.  Characteristic determination of RF8-No Exercise 
(3x/week>20 min) in study population
Characteristic
RF4-Hypoglycaemia
Total N(%) p-value
Yes N (%) No N (%)
Gender
 Male
 Female
Ethnic
 Malay
 Chinese
 Indian
Diagnosis
 IDDM
 Diabetes
 Diabetes and HPT
 Diabetes and other
 complication
Medication 
consideration
 Insulin
 Insulin and oral
 BIDS
 Oral
 Diet and exercise 
14 (9.3)
8 (5.4)
7 (9.2)
7 (4.5)
8 (12.3)
2 (66.7)
9 (10.1)
7 (6.9)
4 (3.8)
2 (33.3)
4 (16.7)
1 (5.6)
13 (5.3)
-
136 (90.7)
139 (94.6)
69 (90.8)
149 (95.5)
57 (87.7)
1 (33.3)
80 (89.9)
94 (93.1)
100 (96.2)
4 (66.7)
20 (83.3)
17 (94.4)
233 (94.7)
3 (100.0)
150 (100.0)
147 (100.0)
76 (100.0)
156 (100.0)
65 (100.0)
3 (100.0)
89 (100.0)
101 (100.0)
104 (100.0)
6 (100.0)
24 (100.0)
18 (100.0)
246 (100.0)
3 (100.0)
0.457
0.317
0.016*
0.033*
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Hypoglycemic evidence has an association with 
diagnosis class and medication consideration, 
no signifi cant diff erences has been found among 
gender and ethnicity of the study population (Ta-
ble 9). Majority of the patients having no social 
habit of exercise, table 10 describes the relation 
and association of no-exercise risk factors with 
characteristic variables among study population. 
Discussion
Th e World Health Organization projects that by 
the year 2025 more than 5% of the world popula-
tion, i.e. 300 million people will suff er from diabe-
tes. A patient who suff ers from type 2 diabetes has 
a 2–4 times greater risk of death from cardiovas-
cular causes than the patient without diabetes (27). 
Th e most Hypertension and Diabetes 83 common 
cause of dying in the diabetic patient is heart dis-
ease. In addition, peripheral vascular disease, end-
stage renal disease, blindness and amputations 
are common co-morbidities in diabetic patients.
Hypertension has been identifi ed as a major risk 
factor for the development of diabetes. Patients 
with hypertension are at a 2–3 times higher risk 
of developing diabetes than patients with normal 
blood pressure (28). Hypertension by itself is, of 
course, a powerful risk factor for cardiovascular 
morbidity and mortality as established by data 
from the Framingham cohort more than three 
decades ago. For any given level of systolic blood 
pressure, the occurrence of diabetes distinctly
increases cardiovascular mortality. Stamler et 
al. (29) have documented that diabetes in the 
normotensive patient confers greater risk than a 
systolic blood pressure between 160 and 170mm 
Hg. Th is observation provoked Haff ner and Cas-
sells’ (30) observation that the prognosis of dia-
betes is just as grim as the one of a patient who 
has suff ered an acute myocardial infarction. Of 
note, while this is true for overall cardiovascu-
lar mortality, it does not necessarily mean that 
diabetes and hypertension are synonymous in 
aff ecting the individual components of cardio-
vascular system. Also, it does by no means fol-
low that specifi c cardiovasculardrugs are equally 
protective in diabetes and coronary artery disease.
Blood pressure control remains unacceptably low 
in the general population, but is even lower in the 
diabetic hypertensive patient (31). Although con-
trolling the blood pressure is a commendable goal 
of antihypertensive therapy, treating hypertensive 
cardiovascular disease in the diabetic patient is 
more complex than simply achieving blood pres-
sure targets. Recent studies have shown that antihy-
pertensive drug classes have diff ering eff ects on the 
risk of new onset diabetes, on metabolic endocrine 
surrogate endpoints and possibly on outcome (32).
Clinical fi nding in cardiovascular problems
in Diabetes patients
Diabetes mellitus is associated with a high risk of 
cardiovascular disease and is the leading cause 
of end-stage renal disease, blindness, and non-
traumatic amputations in western countries (33). 
Elevated but nondiabetic levels of fasting glucose 
also carry a higher risk of cardiovascular disease 
(34). As a cardiovascular risk factor, glycemia is 
a continuous variable with no sudden increase 
in risk (35). Th e extreme state is the metabolic 
syndrome that is associated with a 2- to 3-fold 
increase in cardiovascular morbidity and mor-
tality (36-38). Hypertension by itself is a power-
ful risk factor for cardiovascular morbidity and 
mortality. Although the eff ects of diabetes mel-
litus and hypertension on the cardiovascular 
system vary somewhat and are oft en distinct, 
their combined presence in the same patient is 
destructive (39). Th e common denominator of 
hypertensive/ diabetic target organ disease is the 
vascular tree, which is aff ected by both disorders.
Th e Vascular Tree. Both hypertension and diabe-
tes are well-identifi ed risk factors for atherogen-
esis. Several mechanisms acting together mediate 
the damage to the vascular tree in the diabetic 
hypertensive patient (39). Metabolic abnormali-
ties that oft en present in diabetic hypertensive 
patients accelerate atherosclerosis. Plasma levels 
of lipoprotein have been noted to be elevated in 
diabetic individuals, particularly those with poor 
glycemic control. Augmented oxidation of low-
density lipoprotein cholesterol and formation of 
glycated low-density lipoprotein, which enhance 
foam cell formation, have been observed in dia-
betic states. Anatomic and functional abnormali-
ties of the vascular endothelium have been de-
scribed in diabetes mellitus and hypertension (39).
Hyperglycemia activates protein kinase C in endo-
thelial cells, which may enhance vascular tone, per-
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meability, and atherosclerosis. Elevated circulating 
levels of insulin as exist in type 2 diabetes and in 
many patients with essential hypertension may 
contribute either directly or in conjunction with 
insulin-like growth factor (IGF) to the accelerated 
atherosclerosis associated with these conditions. 
Insulin and IGF-1 may exert their atherogenic ef-
fects through infl uences on both vascular endo-
thelial cells and vascular smooth muscle cells (39). 
Diabetes mellitus and hypertension are also associ-
ated with hematologic abnormalities that encour-
age thrombosis. Enhanced platelet adhesion and 
aggregation as well as higher than normal levels 
of some coagulation factors contribute to the pro-
coagulation state in diabetic hypertensive patients 
(39). Diabetes seems to be a specifi c risk factor for 
small vessel disease. In contrast, hypertension, at 
least in its nonmalignant form, seems to aff ect pre-
dominantly the large arteries. Together, the two 
disorders synergistically damage the arterial tree.
Heart and Coronary Artery Disease. Diabetes mel-
litus is associated with a markedly increased prev-
alence of coronary artery disease. Th e prevalence 
of coronary artery disease as assessed by various 
diagnostic methods is as high as 55% among adult 
patients with diabetes mellitus as compared to 
2–4% of the general population (40). Moreover, 
the cardiovascular mortality rate is more than dou-
bled in men and more than quadrupled in women 
who have diabetes mellitus compared to those 
without. Th e restenosis rate aft er coronary bal-
loon angioplasty is about 2-fold higher in diabetic 
than nondiabetic patients (41). Due to autonomic 
neuropathy diabetic patients have a decreased per-
ception of ischemic pain, which contributes to a 
high prevalence of silent ischemia (42). Diabetic 
patients without previous myocardial infarction 
have as high a risk of myocardial infarction as 
nondiabetic patients with previous myocardial 
infarction (43). Myocardial ischemia is common 
in patients with hypertension (44) and caused by 
several pathogenic mechanisms. (a) Hypertension 
accelerates arteriosclerosis of the coronary arter-
ies. (b) Elevated blood pressure increases left  ven-
tricular wall stress, wall tension, and stroke work. 
(c) Resistance of the coronary microvasculature is 
abnormally elevated in hypertensive patients even 
in the absence of left  ventricular hypertrophy. (d) 
Long-standing hypertension causes left  ventricular 
hypertrophy that increases the diff usion distance, 
compromises the vasodilator reserve of the coro-
nary circulation and increases the oxygen demand 
of the myocardium (27, 45). It should be noted that 
hypertensive patients, especially those with left 
ventricular hypertrophy, are as susceptible to silent 
myocardial ischemia as patients with diabetes (46).
Coronary artery disease is much more com-
mon in diabetic hypertensive patients than in 
patients suff ering from hypertension or diabetes 
alone (47). For all 2,681 men in the PROCAM 
trial who had none of the three risk factors (i.e. 
hypertension, diabetes, or hyperlipidemia), the 
coronary artery disease incidence was 6/1,000 
in 4 years. In contrast, the incidence of coronary 
artery disease in those participants who were suf-
fering from hypertension or diabetes was 14 and 
15 per 1,000 in 4 years, respectively. When both 
risk factors were present in the same patient, the 
incidence rate increased to 48 per 1,000 (47). 
Diabetes, and to a lesser extent hypertension, may 
alter the perception of ischemic pain, leading to 
a high prevalence of silent ischemia. Melina et al. 
(35) found a high prevalence of asymptomatic ST 
segment depression in diabetic patients with es-
sential hypertension. Th e number of ST segment 
depression episodes was signifi cantly related to 
glycosylated hemoglobin levels, left  ventricu-
lar mass, and ambulatory systolic and diastolic 
blood pressure variability and hypertensive peaks.
Hyperlipidemia
Lipoprotein Pattern in Diabetes. Th e most typi-
cal lipoprotein pattern in diabetes, also known as 
diabetic dyslipidemia or atherogenic dyslipidemia, 
consists of moderate elevation in triglyceride lev-
els, low HDL cholesterol values, and small dense 
LDL particles. Th is lipoprotein pattern is associ-
ated with insulin rsistance and is present even be-
fore the onset of diabetes. LDL cholesterol levels 
in type 2 diabetic subjects are generally similar 
to those found in the general population. Small 
dense LDL particles are highly atherogenic be-
cause of their enhanced susceptibility to oxidative 
modifi cation and increased uptake by the arterial 
wall. At triglyceride levels > 132 mg/dl, small LDL 
particles become common (49). Overall, 30–40% 
of patients with diabetes have triglyceride levels > 
200 mg/dl, and 10% have triglycerides > 400 mg/
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dl (50). However, in the U.K. Prospective Diabe-
tes Study, despite a high frequency of modestly el-
evated baseline triglyceride levels (mean baseline 
159 mg/dl), a multivariate analysis showed that 
triglyceride levels did not predict CHD events. 
LDL cholesterol was the strongest independent 
predictor of CHD followed by HDL cholesterol, 
(51) supporting current national guidelines in 
which LDL lowering is the primary lipid target.
Diabetes management
Improving glycemic control in individuals with 
moderate to severe hyperglycemia regardless of 
type of treatment is associated with improvement 
in lipid values. Among the available oral thera-
peutic options for type 2 diabetes, treatment with 
metformin and thiazolidinediones has been as-
sociated with benefi cial eff ects on lipids. Metfor-
min has been associated with modest reduction 
in triglyceride levels in hyperlipidemic and hyper-
tensive patients (52). In a head-to-head compari-
son study, (53) pioglitazone was associated with 
signifi cant triglyceride reduction, whereas there 
was no net triglyceride change with rosiglitazone. 
Although both agents increased HDL cholesterol 
and LDL cholesterol, pioglitazone was associated 
with a greater increase in HDL cholesterol and 
less LDL cholesterol increase than rosiglitazone.
Smoking
Smokers with Type 1 and Type 2 diabetes are at in-
creased risk of illness and premature death, mostly 
through development of cardiovascular disease, 
but other disease processes associated with dia-
betes may also be made worse by smoking (54-
55). Smokers with Type 1 diabetes in particular 
may have a higher risk of developing kidney dis-
ease, and possibly eye and nerve damage as well, 
whereas smokers with Type 2 diabetes are more 
likely to increase their risk of coronary heart dis-
ease, stroke and peripheral vascular disease (56). 
Evidence is also accumulating that shows that 
smoking is associated with an elevated risk of de-
veloping Type 2 diabetes (57-62). A major review 
and meta-analysis of published data has found 
that current smokers are more likely to develop 
diabetes than ex-smokers and never smokers, and 
that smokers of 20 or more cigarettes a day are 
at greater risk than lighter smokers (63). Overall, 
current smokers are estimated to have a 44% great-
er risk, and ex-smokers a 23% greater risk of devel-
oping Type 2 diabetes than people who have never 
smoked (63). Plausible biological mechanisms for 
this association include increased insulin resis-
tance, altered insulin secretion and other impair-
ments to pancreatic function noted in smokers 
(63). According to the authors of this review, 'the 
relevant question should no longer be whether 
this association exists, but rather whether this es-
tablished association is causal.'(63 p2660) If fur-
ther research proves a causal relationship between 
smoking and Type 2 diabetes, it can be expected 
to have a major impact on future estimates of to-
bacco-caused morbidity and mortality in Austra-
lia and globally. Smokers experience a poorer level 
of overall general health than non-smokers (64). 
Taking into account possible confounding factors 
such as alcohol use, socioeconomic background, 
age and gender, smokers also report higher lev-
els of tiredness or fatigue, reduced wellbeing and 
satisfaction with life, slightly lower self-reported 
measures of mental wellbeing, and increased in-
cidence of psychological symptoms such as de-
pressed mood and anxiety. In the elderly, smok-
ing is associated with accelerated declines in 
physical function, and increased levels of clinical 
illness and physical and cognitive impairment 
(64). Smokers are also more likely to report a 
history of pain during health examinations (65). 
It is understood that the circulation throughout 
the body of toxic constituents of tobacco smoke 
causes a number of diseases of many organs, as 
detailed in the preceding sections. Th e widespread 
distribution of tobacco smoke components may 
also be responsible for a more general decrement 
in health, through altered infl ammatory/immune 
processes, oxidative stress and subclinical organ 
injury (64). Smokers are also more likely to experi-
ence sleep disturbances, including taking longer to 
fall asleep, being less likely to stay asleep, and hav-
ing less total sleep time than non-smokers (66-67).
Smoking and absence from work due to illness. 
Smokers are more likely to miss work due to ill-
health, have longer duration of absence from work, 
and access all levels of medical care more frequent-
ly. Work absences are reportedly higher in smok-
ers resulting from a broad range of symptoms, 
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including problems with the digestive tract, neck, 
back and upper limbs. Th ese eff ects are evident 
in younger smokers, before the eff ects of major 
tobacco-caused disease become apparent during 
middle age and later years.5 Th ere is also substan-
tial evidence that smokers are more likely to suff er 
injury in the workplace than non-smokers (64).
Australian data show that men who smoke are 
66% more likely to be absent from work than 
male never-smokers, and that female smokers are 
23% more likely to miss work than female never-
smokers (68). Th is in turn has a major quantifi able 
economic impact on the nation's productivity (69).
Hypoglycaemia
Low blood sugar, also called hypoglycemia, is a 
condition that occurs when the amount of sugar in 
a patient's blood is lower than normal. Blood sugar 
levels less than 70 mg/dL are considered to be dan-
gerously low and may cause damage to the patient's 
tissues, reports MedlinePlus, a National Institutes 
of Health website (70). Hypoglycemia can cause 
a variety of long-term eff ects or complications.
Defi ciencies in Neurodevelopment
Newborn babies, or neonates, who suff er from 
recurrent episodes of low blood sugar levels can 
develop defi ciencies in neurodevelopment, states 
an article in the April 1999 issue of the Journal 
of Pediatrics (72). Neurodevelopment pertains 
to the growth and maturation of the brain and 
other aspects of the nervous system. Neonates, 
especially premature babies, who have been af-
fected by hypoglycemia, may have reduced 
head circumferences and score lower on psy-
chometric tests. Th ese eff ects can last up to fi ve 
years aft er birth. Even mild to moderate cases 
of hypoglycemia in neonates should be treated 
promptly to avoid these long-term complications.
Coma
Coma, or chronic loss of consciousness, may be 
a long-term eff ect of hypoglycemia, according to 
MedlinePlus (70). Hypoglycemia that results in 
coma is commonly called insulin shock. With-
out adequate levels of blood sugar, the brain is 
unable to obtain enough energy to function. De-
creased brain function over a long period of time 
typically results in coma. Patients in a coma are 
unresponsive to external stimuli and may need as-
sistance breathing and ingesting nutrients. Comas 
may last between a few hours to several months. 
Treating the hypoglycemic disorder usually 
brings the patient back to a conscious state (71).
Death
Without sugar, or glucose, the body is unable to 
function. Glucose provides much of the energy 
the body needs to survive. As blood sugar levels 
fall, multiple organs, especially the brain, begin 
to fail, warns MayoClinic (71). If left  untreat-
ed, this condition may lead to death. Patients 
must recognize the early signs of hypoglyce-
mia in order to avoid this dreaded outcome (72).
Physical Activity
Th e possible benefi ts of physical activity for the 
patient with type 2 diabetes are substantial, and 
recent studies strengthen the importance of long-
term physical activity programs for the treatment 
and prevention of this common metabolic ab-
normality and its complications. Specifi c meta-
bolic eff ects can be highlighted as follows (73). 
Glycemic control several long-term studies have 
demonstrated a consistent benefi cial eff ect of 
regular physical activity training on carbohydrate
metabolism and insulin sensitivity, which can 
be maintained for at least 5 years (74-75). Th ese 
studies used physical activity regimens at an 
intensity of 50–80% Vo2max three to four 
times a week for 30–60 min a session (74). 
Improvements in HbA1c were generally 10–20% 
of baseline and were most marked in patients with 
mild type 2 diabetes and in those who are likely 
to be the most insulin resistant (76). It remains 
true, unfortunately, that most of these studies suf-
fer from inadequate randomization and controls, 
and are confounded by associated lifestyle changes 
(77). Data on the eff ects of resistance exercise are 
not available for type 2 diabetes although early 
results in normal individuals and patients with 
type 1 disease suggest a benefi cial eff ect (73, 75).
It now appears that long-term programs of regu-
lar physical activity are indeed feasible for pa-
tients with impaired glucose tolerance or un-
complicated type 2 diabetes with acceptable 
adherence rates (79). Th ose studies with the 
best adherence have used an initial period of su-
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pervision, followed by relatively informal home 
physical activity programs with regular, frequent 
follow-up assessments (80). A number of such 
programs have demonstrated sustained relative 
improvements inVo2max over many years with 
little in the way of signifi cant complications (81).
Exercise and Type 1 Diabetes 
All levels of physical activity, including leisure 
activities, recreational sports, and competitive 
professional performance, can be performed 
by people with type 1 diabetes who do not have 
complications and are in good blood glucose 
control (note previous section) (76-78). Th e 
ability to adjust the therapeutic regimen (in-
sulin and medical nutrition therapy) to al-
low safe participation and high performance 
has recently been recognized as an important 
management strategy in these individuals (77). 
In particular, the important role played by the 
patient in collecting self-monitored blood glu-
cose data of the response to physical activity and 
then using these data to improve performance 
and enhance safety is now fully accepted (73-75). 
Hypoglycemia, which can occur during, imme-
diately aft er, or many hours aft er physical activ-
ity, can be avoided. Th is requires that the patient 
has both an adequate knowledge of the metabolic 
and hormonal responses to physical activity and 
well-tuned self-management skills (76). Th e in-
creasing use of intensive insulin therapy has 
provided patients with the fl exibility to make ap-
propriate insulin dose adjustments for various 
activities (79). Th e rigid recommendation to use 
carbohydrate supplementation, calculated from 
the planned intensity and duration of physical 
activity, without regard to glycemic level at the 
start of physical activity, the previously measured 
metabolic response to physical activity, and the 
patient’s insulin therapy, is no longer appropriate. 
Such an approach not infrequently neutralizes 
the benefi cial glycemic lowering eff ects of physi-
cal activity in patients with type 1 diabetes (80).
General guidelines that may prove helpful in 
regulating the glycemic response to physical 
activity can be summarized as follows (73-76):
1. Metabolic control before physical activity 
- Avoid physical activity if fasting glucose lev-
els are _250 mg/dl and ketosis is present, and 
use caution if glucose levels are _300 mg/dl 
and no ketosis is present. Ingest added car-
bohydrate if glucose levels are _100 mg/dl.
2.  Blood glucose monitoring before and af-
ter physical activity - Identify when 
changes in insulin or food intake are nec-
essary. Learn the glycemic response to 
diff erent physical activity conditions.
3. Food intake - Consume added carbohy-
drate as needed to avoid hypoglycemia. 
Carbohydrate-based foods should be read-
ily available during and aft er physical activity.
Because diabetes is associated with an increased 
risk of macrovascular disease, the benefi t of 
physical activity in improving known risk factors 
for atherosclerosis is to be highly valued. Th is is 
particularly true in that physical activity can im-
prove the lipoprotein profi le, reduce blood pres-
sure, and improve cardiovascular fi tness (76).
However, it must also be appreciated that several 
studies have failed to show an independent eff ect 
of physical activity training on improving glycemic 
control as measured by the A1C test in patients 
with type 1 diabetes. Indeed, these studies have 
been valuable in changing the focus for physical ac-
tivity in diabetes from glucose control to that of an 
important life behavior with multiple benefi ts (76, 
80). Th e challenge is to develop strategies that al-
low individuals with type 1 diabetes to participate 
in activities that are consistent with their lifestyle 
and culture in a safe and enjoyable manner (78).
In general, the principles recommended for deal-
ing with physical activity in adults with type 1 
diabetes, free of complications, apply to chil-
dren, with the caveat that children may be prone 
to greater variability in blood glucose levels. In 
children, particular attention needs to be paid to 
balancing glycemic control with the normalcy of 
play, and for this the assistance of parents, teachers, 
and athletic coaches may be necessary. In the case 
of adolescents, hormonal changes can contrib-
ute to the diffi  culty in controlling blood glucose 
levels (3,54, 70). Despite these added problems, 
it is clear that with careful instructions in self-
management and the treatment of hypoglycemia, 
physical activity can be a safe and rewarding expe-
rience for the great majority of children and ado-
lescents with type 1 diabetes (15, 27, 31, 54, 72).
Exercise in the Elderly
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Evidence has accumulated suggesting that the 
progressive decrease in fi tness and muscle mass 
and strength with aging is in part preventable by 
maintaining regular physical activity (81). Th e 
decrease in insulin sensitivity with aging is also 
partly due to a lack of physical activity. Lower lev-
els of physical activity are especially likely in the 
population at risk for type 2 diabetes (1, 81). A 
number of recent studies of exercise training have 
included signifi cant numbers of older patients 
(49, 78). Th ese patients have done well with good 
training and metabolic responses, levels of adher-
ence at least as good as the general population, and 
an acceptable incidence of complications (49). It 
is likely that maintaining better levels of fi tness 
in this population will lead to less chronic vas-
cular disease and an improved quality of life (57).
Conclusion
Majority of patients are at high risk of long-term 
complications and comorbidies. It has been 
found that increased rate of risk factors have 
been found among the study population and 
non-signifi cant to sociodemographic diff erences. 
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